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Abstract
BACKGROUND—Babesiosis is an emerging tick-borne infection in humans. The increasing 
numbers of reported cases of transfusion-associated babesiosis (TAB), primarily caused by 
Babesia microti, represents a concern for the safety of the U.S. blood supply.
STUDY DESIGN AND METHODS—This study investigated kinetics of parasitemia, innate 
immune responses and dynamics of antibody responses during B. microti infection in rhesus 
macaques using blood smears, quantitative PCR (qPCR), flow cytometry, and indirect fluorescent 
antibody testing. A total of 6 monkeys were transfused with either hamster or monkey-passaged B. 
microti infected erythrocytes (2 and 4 monkeys, respectively) simulating TAB.
RESULTS—The prepatent period in monkeys inoculated with hamster-passaged B. microti was 
35 days compared with 4 days in monkeys transfused with monkey-passaged B. microti; the latter 
monkeys also had markedly higher parasitemia levels. The duration of the window period from the 
first detected parasitemia by qPCR analysis to the first detected antibody response ranged from 
10–17 days. Antibody responses fluctuated during the course of the infection. Innate responses 
assessed by the frequencies of monocytes and activated B cells correlated with the kinetics and 
magnitude of parasitemia. On day 14, additional activation peaks were noted for CD14+CD16+ 
and CD14−CD16+ monocytes and for CD11c+ myeloid dendritic cells, but only in animals 
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transfused with monkey-passaged B. microti. Parasitemia persisted in these immunocompetent 
animals, similar to human infection.
CONCLUSION—The results suggest that transfusion-associated transmission of B. microti leads 
to rapid onset of parasitemia (day 4) in rhesus macaques, detectable antibody response 14 days 
later and persistent parasitemia.
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INTRODUCTION
Babesiosis is a tick-borne disease caused by intraerythrocytic parasites, including Babesia 
microti and other Babesia species.1,2 Babesia infection can range from asymptomatic to 
severe.1,3,4 In severe or persistent cases who require treatment, clindamycin and quinine5 or 
an alternative regimen using atovaquone and azithromycin have been recommended.6 B. 
microti infection is not usually clinically silent,7,8 complications of B. microti include 
hemolytic anemia, acute respiratory distress syndrome, disseminated intravascular 
coagulopathy, congestive heart failure, hepatic failure, splenic rupture and renal failure. 9–12 
In particular, persons who are asplenic, elderly, or otherwise immunocompromised are at 
increased risk for clinical manifestations and life-threatening infection.1,3,4
Transfusion-associated babesiosis (TAB) is a growing public health concern for the safety of 
the US blood supply since it may lead to severe morbidity and mortality. Babesiosis became 
a nationally notifiable disease in January 2011.13 B. microti has been implicated in the 
majority of US tick-borne and TAB cases, including 159 of the 162 cases of TAB that were 
identified during the period of 1979–2009; the other 3 cases were caused by B. duncani.13 
These figures likely underestimate the actual number of TAB cases, as infections are not 
always diagnosed nor recognized as transfusion-associated and investigated.13 In the United 
States, B. microti is endemic in parts of the Northeast and upper Midwest, whereas sporadic 
cases of infection with B. duncani have been identified in several western states.13 Acute, 
symptomatic cases of babesiosis typically are diagnosed by light-microscopic identification 
of organisms on Giemsa-stained thin blood smears.9,14 B. microti elicits both IgM and IgG 
antibody responses in humans, and serologic testing is commonly used as evidence for 
transmission in retrospective investigations of donors,15–17 although recent attempts to 
detect Babesia nucleic acids in blood products have been made to confirm transmission.17–19 
In addition, investigational high throughput antibody screening assays including Enzyme 
immunoassay (EIA) and arrayed fluorescence immunoassay (AFIA) showed promising 
results for donor screening. 17,20,21 FDA has closely monitored the results of an 
investigational protocol evaluating B. microti serology and PCR and recently solicited 
formal input from an advisory committee on appropriate screening methodology and donor 
deferral, but has yet to define a temporary deferral period for donors who have tested 
positive for B. microti.21
Nonhuman primates–particularly, rhesus macaques (RMs) are the most widely used animal 
models of human disease because of their close genetic, physiologic, and metabolic 
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similarity to humans.22 RMs have been used successfully to study the kinetics of B. microti 
parasitemia.23–25 However, these studies did not document the acute innate immune 
responses during B. microti parasitemia, as well as before and after seroconversion. Further, 
immune responses to B. microti infection have been evaluated in a limited number of 
studies.26,27 Such issues are central to developing effective strategies to prevent TAB, 
including an automated high-throughput assay for B. microti donor screening. Therefore, we 
conducted a formal, comprehensive investigation using the RM animal model to fill key gaps 
and model human TAB with B. microti.
MATERIALS AND METHODS
Ethics statement
All RMs were born at Yerkes National Primate Research Center (YNPRC) and were 
maintained at the YNPRC of Emory University in accordance with the regulations of the 
Guide for the Care and Use of Laboratory Animals, 8th edition. YNPRC has been fully 
accredited by the Association for Assessment and Accreditation of Laboratory Animal Care 
International since 1985. The experiments were approved by the Emory Institutional Animal 
Care and Use Committee as well as biosafety review board. The animals were fed monkey 
diet (Purina) supplemented daily with fresh fruits or vegetables and water ad libitum. 
Additional social enrichment, including the delivery of appropriate safe toys, was provided 
and overseen by the Yerkes enrichment staff, and animal health was monitored daily and 
recorded by the animal care staff and veterinary personnel, available 24 hours, 7 days a 
week. Monkeys were caged in socially compatible same-sex pairs to facilitate social 
enhancement and well-being. Male Golden Syrian Hamsters (Mesocricetus auratus) were 
used to propagate B. microti Gray strain parasites in accordance with the rules and 
regulations within CDC animal use protocol “Production of antigen in hamsters and gerbils 
for the serodiagnosis of babesiosis”.
Study design and experimental infections
The study was conducted in three different phases as illustrated in Figure 1. A total of 6 
adult (7–13 years), female, non-splenectomized, Indian RMs were assigned to this study, 
specifically 2 monkeys for phase 1 (RFl9, RGc8), 3 monkeys in phase 2 (RLk10, RZz9, 
RCq10), and 1 animal for phase 3 (RVf12). All the animals were prescreened to rule out 
prior malaria and/or Babesia infection using blood smears, PCR and IFA test. The animals 
were pretreated with diphenhydramine prior to exposure to B. microti to prevent potential 
anaphylaxis. Since B. microti cannot be grown in vitro, freshly collected blood from 
parasitemic hamsters was utilized as the source of primary inoculation for phase 1. Each of 
the 2 RMs was inoculated with 2.8 mL of heparinized hamster blood intravenously 
containing approximately 6×109 hamster-passaged B. microti Gray strain. After inoculation, 
blood samples were collected aseptically from the femoral vein in EDTA on days 1, 4, 7, 14 
and weekly thereafter (Figure 1), for PCR, IFA, flow cytometry, Giemsa-stained thin/thick 
blood smears, complete blood count and chemistry analyses. Blood smears were also 
prepared from blood obtained by ear prick procedure to determine the parasitemia at various 
time points (Figure 1). On day 56, 10 mL blood from each phase 1 monkey was harvested 
and erythrocytes from each animal were washed in 7.5 mL normal saline and mixed together 
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to a total volume of 15 mL for transfusion into three phase 2 monkeys (Figure 1). Blood 
smears from pooled blood sample were also prepared to estimate parasitemia. Each phase 2 
animal was inoculated intravenously with 5 mL of infected erythrocytes and saline mixture 
corresponding to approximately 1.5×107 organisms of monkey-passaged B. microti obtained 
from phase 1. On day 63 of phase 2, blood was collected from RM RCq10, in which B. 
microti had become undetectable in both thin and thick blood smears but remained positive 
by IFA and PCR, to test whether transfusion of such blood had the potential to transmit 
Babesia. Five mL of washed erythrocytes corresponding to a total dose of 25,000 monkey-
passaged B. microti (based on qPCR) from phase 2 were prepared as described above and 
transfused intravenously to RM RVf12 (phase 3). In phase 3, additional blood samples were 
collected on days 10, 12, and 18. All animals in this study were treated for 10 days with 
atovaquone (Amneal Pharmaceuticals) @ 20 mg/kg orally twice a day and azithromycin 
(Greenstone Limited) @ 12 mg/kg orally once a day starting on day 122. The animals were 
monitored thereafter by blood collections at various time points to document that no 
parasites were found and to conduct additional analyses as described above. Phase 1 and 3 
animals (Figure 1) needed a second course of treatment starting on days 193 and 200, 
respectively, to achieve parasitic clearance.
Estimation of parasitemia by light microscopy
Peripheral blood thin and thick smears were prepared from EDTA whole blood, stained with 
Wright-Giemsa stain. Thin blood smears were used for parasite identification and thick 
blood smears for quantification of organisms detected as described previously.28 Parasitemia 
was expressed as parasites/μL of blood in a thick blood film by counting parasites until 200 
sequential WBCs were enumerated and using the simple mathematical formula: 
Nested PCR (nPCR) and Quantitative PCR (qPCR)
DNA isolation was performed on 200 μL of EDTA whole-blood using QIAamp DNA Blood 
Mini Kit using the QIAcube automated system (QIAGEN, CA). Detection of B. microti 
DNA was performed in a nPCR assay as described elsewhere,29 with some modifications. 
For qPCR, a standard curve was created by serially diluting three blood samples from 
experimentally infected hamsters with known parasitemia levels, corresponding to 220,000, 
935,000 and 1,280,000 parasites/μL, respectively (Figure S1). qPCR was performed using a 
published TaqMan real-time PCR assay targeting the 18S rRNA gene.30 Each sample was 
run in triplicate with appropriate negative and positive controls. The Ct-values were 
compared to the standard curve to derive numbers of parasites present in the RM samples. 
Parasitemia was expressed as parasites/μL of blood.
Indirect fluorescent antibody test
An IFA assay for IgG antibodies to B. microti was used as described earlier.31 Briefly, sera 
were diluted fourfold starting at 1:4 to 1:4096. 20 μL of sera was added to the appropriate 
well on the coated B. microti slides and incubated for 30 min at 37°C. Slides were washed 
for 5 min with PBS and dried followed by addition of 20 μL goat anti-human 
immunoglobulin cross reacting with rhesus immunoglobulin labeled with fluorescein (FITC, 
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1 mg/mL) at 1:50 in PBS with 0.1% Evans blue and were incubated for 30 min at 37°C. The 
fluorescence was determined with an Olympus BX60 microscope equipped with a X-cite 
Series 120–Q fluorescence illumination source at 400× magnification. A titer of 1:64 with B. 
microti antigen was considered a positive reaction.
Flow cytometry
Freshly isolated peripheral blood mononuclear cells (PBMC) (~1×106) were stained with 
three fluorescent antibody panels with predetermined concentrations of antibodies against 
CD3 (SP34-2), CD4 (L200), CD8 (RPA-T8), CD20 (L27), CD28 (CD28.2), CD95 (DX2), 
NKG2A (Z199), HLADR (Tu36), CD38 (AT-1), CD14 (M5E2), CD16 (3G8), CD11c (3.9), 
CD123 (7G3), CD21 (B-Ly4), CD27 (MT271), CD127 (R34.34), CD25 (4E3), CD86 
(IT2.2), CD25 (1HT44H32) (Table S2). Cells were incubated with the antibody cocktails for 
30 min at 4°C, washed with PBS containing 2% FBS, permeabilized with perm/fix buffer 
(BD) washed with 2 mL of perm wash buffer. The cells were then additionally stained with 
anti-Ki67 (B56) or for Foxp3 (206D). Cells were finally fixed in 1% paraformaldehyde, 
acquired on LSR-II flow cytometer driven by FACS DiVa software. Analysis of the acquired 
data was performed using FlowJo software (version 9.4.11; TreeStar).
Statistical analyses
Flow cytometry data were analyzed using a 2-tailed paired t-test to compare activation 
patterns in phase 1 and 2 animals.
RESULTS
Level and duration of parasitemia during B. microti infection
To model TAB in monkeys, we utilized a 3 tiered experimental protocol: The initial phase 
was to generate monkey-adapted B. microti for direct transfusion of “high acute” 
parasitemia (phase 2) and low chronic parasitemia (phase 3). For the xenogeneic transfusion 
(phase 1), patent infection developed in both monkeys inoculated with 6×109 hamster-
passaged B. microti (Gray strain) after 35 and 49 days in the 2 monkeys (RFl9, RGc8) based 
on qPCR and blood smear data, respectively (Figures 2 and S2). The parasitemia peaked on 
day 56 (RGc8) and 63 (RFl9) after experimental infection, and the peak parasitemia detected 
with qPCR and blood smears showed good temporal correlation. Peak parasitemia ranged 
from 1227 to 1679 organisms/μL on thick blood smears or 11,319 to 15,676 organisms/μL 
blood by qPCR. After peak parasitemia, both animals showed intermittent low level 
parasitemia (<50 organisms/μL) prior to initiating drug treatment on day 122. This low level 
parasitemia persisted in RFl9 based on nPCR/qPCR analysis leading to a second round of 
therapy on day 193. Erythrocytes from both phase 1 monkeys were collected on day 56 and 
transfused to phase 2 monkeys (corresponding to 1.5×107 organisms). Even though the 
parasite dose was >100 fold lower than the dose administered to phase 1 monkeys, the 
prepatent period was markedly reduced (4 days). The peak parasitemia identified (qPCR and 
blood smears) on day 14 or day 21 post infection was also markedly higher in 2 of the 3 
phase 2 monkeys compared to phase 1 monkeys (Figure 3). Phase 2 RM RCq10 surprisingly 
exhibited markedly lower peak parasitemia, suggesting individual differences in 
susceptibility. Beyond the acute parasitemia, these monkeys also exhibited intermittently 
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detectable low level chronic parasitemias (<50 organisms/μL) prior to atovaquone/
azithromycin treatment. The intermittent chronic low level parasitemia was detected 
predominantly by nPCR, the most sensitive technique, though confirmed by qPCR followed 
by measurable transient rebounds in IFA titers (Figures 2–4 and Table S1), while parasites 
could not be detected in blood smears beyond the acute infection.
To determine the clinical relevance of low chronic parasitemia, blood collected from RM 
RCq10 at day 63 post transfusion (blood smears with no parasites found and barely positive 
qPCR signal) was transfused to phase 3 monkey (RVf12), amounting to about 25,000 
monkey-passaged B. microti organisms, based on qPCR. However, this low dose exposure 
also resulted in patent infection. The prepatent period was 4 days based on qPCR/nPCR and 
blood smears detected B. microti on day 21. Peak parasitemia was detected on day 35 
(Figure 4, 528 organisms/μL by blood smears and 10,631 organisms/μL by qPCR). RVf12 
also showed intermittently detectable low level parasitemia (<50 organisms/μL) on blood 
smears until day 70 followed by nPCR/qPCR detection prior to starting treatment on day 
122. This animal, similar to phase 1 RFl9 required a 2nd course of treatment to eliminate 
detectable parasite.
The kinetics and detection of parasitemia have been summarized in Table 1 and Figures 2–4, 
suggesting clear differences in prepatency depending on the source of the TAB, while peak 
parasitemia in animals transfused with monkey-passaged B. microti appear to reflect the 
infectious dose, though phase 3 only comprised 1 animal. There was fluctuation of 
parasitemia after the acute peak with no pattern in the timing of recurrences of detectable 
parasitemia during chronic infection.
Of note, clinical symptoms, e.g. flu-like illness, and deviations in hematological parameters 
(hemoglobin, hematocrit, WBC or differential counts) were not observed in these animals.
Antibody responses during and after B. microti infection
The kinetics of parasitemia and antibody titers are summarized in Table 1 and Figures 2–4. 
During phase 1, the first antibody IFA responses (1:64) were detected on days 35 and 49, on 
the day of, or 2 weeks after the first qPCR detection for RGc8 and RFl9, respectively. The 
peak antibody titers (1:4096) in both animals were detected on day 56 coinciding with peak 
parasitemia. The antibody titers gradually declined to 1:1024 on day 84, and lower levels 
(1:64) were still observed for RGc8 on day 207. Conversely, RFl9’s titer fluctuated, and a 
titer of 1:1024 was observed on day 207 despite the absence of detectable parasitemia. In 
phase 2, the first positive antibody titers (1:256) were detected on day 14 i.e. 10 days after 
the first detectable parasitemia. Peak antibody titers were identified on day 21 again, 
coinciding with the peak parasitemia. Of note, peak antibody titers in 2 of the 3 phase 2 RMs 
and the phase 3 RM were markedly lower than in phase 1 monkeys. The first antibody 
detection in the phase 3 monkey was on day 21, likely attributable to the comparatively 
small inoculum transfused. With the exception of RCq10, the peak antibody titers rapidly 
declined in all animals, though fluctuations in antibody titers were noted for the monkeys 
transfused with monkey-passaged Babesia but not with hamster-passaged parasites, 
suggesting occasional parasite replication which is not necessarily detectable in blood.
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Innate immune responses to B. microti infection
We hypothesized that B. microti infection invokes innate responses in vivo. Therefore, we 
monitored PBMCs at periodic intervals over the course of the study to address changes and 
activation of various cell lineages. Evidence of immune activation was most clearly observed 
in B cells, T cells, monocytes, and myeloid dendritic cells, whereas changes in NK cells 
(NKG2a+) or T regulatory cells (CD25+/FoxP3+/CD127−) were not observed in blood. As 
expected for parasite driven responses, the kinetics for immune activation paralleled those of 
parasite burden. B cell activation/proliferation—assessed by the frequency and density of 
Ki67 expression on CD20+ cells—showed a biphasic increase on days 7 and 49 in both 
phase 1 animals (Figure 5). In the phase 2 monkeys, B cell activation peaked sharply on day 
7 and decreased thereafter towards baseline values by day 21 or 35. Activation of B cells in 
the phase 3 animal was weaker, which may reflect the comparatively low inoculum. For all 6 
monkeys, the peak activation was essentially reflective of tissue memory (CD21−/CD27−, 
p=0.0441 on day 7) and of memory (CD21−/CD27+; p=0.0198 on day 7 and p=0.0012 on 
day 14 relative to baseline) B cell subsets, whereas the naïve B cell subsets (CD21+/CD27−) 
did not show such change (not shown).
Activation of T cells was predominantly seen in the CD8+ central memory T cells (Tcm) 
(CD28+CD95+) on day 7 post transfusion for animals infected with monkey-passaged B. 
microti, as measured by the percentages of Ki67+ and HLA-DRhi cells (Figure S3), whereas 
such increases in percentages were much more modest in phase 1 animals. In contrast to 
CD8+ cells, CD4+ T cells showed little evidence of activation, except perhaps in a phase 1 
monkey (RGc8; data not shown).
For monocytes and myeloid dendritic cells, activation measured by increases in Ki67 and 
CD86 mean fluorescence intensity demonstrated low and highly variable levels of activation 
without a clear trend in phase 1 monkeys (data not shown). However, in phase 2 monkeys, 
acute activation was clearly seen on day 14 for activated CD14+/CD16+ and atypical 
CD14−/CD16+ monocytes, as well as for myeloid dendritic cells (Figure S4). This 
activation was highest for RCq10, followed by RLk10 and RZz9, suggesting that activation 
of monocytic lineages was not proportional to the magnitude of parasitemia. Activation of 
these subsets was minimal in the phase 3 monkey (data not shown).
DISCUSSION
In the US, almost 5 million patients are recipients of red blood cells transfusion annually, the 
safety of which remains a constant source of concern.32 Babesiosis is now the most 
commonly reported transfusion-associated parasitic disease.33,34 Clinical features of TAB 
cases are usually considered similar or more severe than those observed after arthropod 
vectored transmission, primarily due to underlying health-related issues and lowered 
immune competence in blood recipients, promoting the development of clinically manifest 
babesiosis following blood transfusion with a Babesia-contaminated unit.8
While there is increased interest in developing a high-throughput assay for B. microti blood 
donor screening, further research is also needed to understand the kinetics of parasitemia 
and antibody responses. Various experimental animal models have been used to investigate 
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the underlying pathophysiology of Babesia infection, and hamsters are commonly used as a 
model to study babesiosis and explore drug therapies.35,36 Mouse models are usually less 
representative because they develop low grade parasitemia.37 Despite the presence of 
existing rodent models, the pathophysiology of human babesiosis is not completely 
understood. Therefore, in the present study we investigated clinically relevant aspects of 
transfusion-associated transmission of B. microti in a primate model that is physiologically 
closer to man.
Data on duration of B. microti parasitemia or persistence of infection in humans are 
limited.38,39 In this study, the prepatent period in monkeys inoculated with hamster-passaged 
Gray stain cells ranged from 35 to 49 days, and the peak parasitemia on blood smears ranged 
from 1227 to 1679 organisms/μL. Morphologically, the parasites resembled those seen in the 
hamsters, humans and NHP. In the late 1970s and early 1980s, RMs have been used 
successfully to study the kinetics of B. microti parasitemia.23–25 These studies reported a 
prepatent period of 15 to 46 days in monkeys infected with the hamster-passaged Briard 
strain of B. microti, and peak parasitemia ranged from 496 to 3906 organisms/μL. 
Parasitemia persisted for at least 90 days in all the animals and parasites were detected 559 
days after inoculation in one animal, 23 suggesting variability in the ability of B. microti 
strains to replicate in vivo. In addition, recurrences of parasitemia were seen following 
splenectomy in RMs infected intravenously or via B. microti infected nymphal ticks.24,25 
The phase 2 and 3 animals in this study revealed a far shorter prepatent period (4 days) than 
the phase 1 monkeys suggesting a possible host adaptability of B. microti, and a far more 
representative model of TAB in humans. The basis for such variability in parasite dynamics 
between hamster-passaged and monkey-passaged B. microti strains may be secondary to 
parasite genome mutations, or the acquisition of species specific host markers that somehow 
facilitate replication in vivo. It has been reported that comparative studies of parasite 
genomes can reveal genetic adaptations to parasitism.40 However, the extent to which the 
combination of host environment and genetic variation accounts for variability in 
pathogenicity associated with B. microti strains remains to be investigated.
The possibility of asymptomatic persistence of B. microti in blood donors is supported by 
numerous TAB cases.13,41,42 A recent study documented that seropositive donors can have 
protracted low level parasitemia,38 which was corroborated in the present study up to the 
time that the monkeys received antimicrobial therapy. The possible explanation of recurrent 
parasitemia in this study could be due to combination of premunition (concomitant 
immunity) and/or process of “antigenic variation” which has been reported to occur in 
Babesia spp. including B. microti and is thought to aid Babesia spp. survival by evasion of 
host adaptive immune responses.43–45
One major challenge posed by this mostly clinically silent infection is the possibility of 
persistent parasitemia that is below the level of detection of currently available tests. As seen 
here, detection of parasites in blood smears, the current reference for patient diagnosis in 
acutely ill patients, including transfusion recipients, is relatively insensitive, and absence of 
Babesia detection by this method does not exclude the possibility of parasite transmission to 
transfusion recipients (Figures 3, 4). Although the number of animals available to us did not 
allow for extensive testing of transmission during chronic Babesia infection, the 
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transmission of B. microti from a phase 2 monkey to the phase 3 monkey readily occurred 
even though qPCR values and nPCR signals at the time of collection were very low (≤5 
organisms/μL of blood), providing proof of concept that such transmission does occur. 
Further, antibody titers measured by IFA were quite variable post infection, and often barely 
positive, despite low (intermittently detectable) levels of Babesia nPCR/qPCR signals, 
suggesting that single nucleic acid based test or IFA assay available to date may not be 
adequate by itself for adequate donor screening to prevent Babesia transmission, particularly 
after the acute phase of Babesia infection. This is not secondary to the sensitivity of 
individual assays but more to the size of the representative samples tested. The findings in 
the current study underscore that the protracted low levels of parasitemia pose a risk for 
transmission. Of note, the transfusion used in our study differs from human blood 
transfusion by the absence of blood storage as in human blood banking conditions. In 
addition, a single course of prescribed atovaquone and azithromycin failed to clear the 
parasites in 3 animals suggesting additional courses of treatment are required for complete 
clearance of B. microti, which requires further investigation. Similar finding has been 
reported in few B. microti infected humans where the subjects were retreated with 
atovaquone and azithromycin due to persistent positive B. microti PCR.38
Little is known also regarding the minimal infectious dose of B. microti which can cause 
infection in naïve hosts. The monkey in phase 3 of this study became infected with a dose of 
25,000 B. microti organisms obtained from 5 mL of erythrocytes harvested during the 
chronic phase of infection even though no parasites could be detected by blood smear. 
Considering the average volume of a human blood transfusion for adults, this dose 
represents approximately 1.5×106 B. microti in a blood unit assuming 300 mL of packed 
RBC/unit. Of note, while the low dose transfused resulted in a delayed peak of parasitemia 
and lower magnitude measured by blood smear, the qPCR parasitemia loads were similar to 
those of the other monkeys transfused with higher Babesia doses.
Innate responses such as monocyte activation has been reported upon infection of monkeys 
with B. microti.46 Another study reported higher frequency of IL-10 producing B cells 
(Bregs) and CD4+CD25+FoxP3+ T cells during the course of B. microti infection in mice.19 
Our study confirmed an early activation of monocyte subsets and myeloid dendritic cells 
corresponding to the peak parasitemia, suggesting a role for these cell lineages in the early 
control of parasitemia. The sharp decline in activation following this time point coincides 
with a drop in parasitemia and it has been demonstrated that in mice, monocyte/
macrophages are important for parasite control.47 Although this study did not examine other 
tissues, it is possible that these monocytes are migrating to tissues such as the spleen where 
they develop into macrophages and assist in the removal of infected erythrocytes. 
Conversely, memory B cells activation preceded the peak of parasitemia, suggesting the 
induction of adaptive responses precedes the peak of parasitemia. Anecdotally, the animal 
with the lowest peak parasitemia (RCq10, phase 2) exhibited the highest level of immune 
activation overall, suggesting that perhaps these responses are indeed involved in the control 
of parasite replication. These responses were transient only, even though low levels of 
parasitemia persisted in most monkeys, suggesting that perhaps Babesia may have developed 
strategies to limit anti-parasitic defenses allowing for its survival at low levels.
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Taken together, the study has enhanced our understanding of B. microti host invasion and 
suggested possible evolutionary adaptation of B. microti strains to a specific host and 
illustrated the complexity of persistence of B. microti. Overall, the antibody response was 
consistently detected 14 days after the first detection of parasitemia. qPCR detected 
infections several days before IFA upon homologous monkey infections while results from 
both techniques were matched for the detection of the hamster derived infections. However, 
the onset of parasitemia was far more rapid during the homologous transfusion. In addition, 
the data presented here provide a potential model to study the complexity of host-parasite 
interaction and the mechanisms of parasite persistence.
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Study design. Phase 1: On day 0, two rhesus macaques were inoculated with erythrocytes 
containing 6×109 hamster-passaged B. microti. In phase 2, three monkeys were transfused 
with 1.5×107 monkey-passaged B. microti obtained on day 56 of phase 1. One monkey in 
phase 3 was transfused with 25,000 monkey-passaged B. microti acquired from a phase 2 
monkey. All animals in this study were treated with atovaquone and azithromycin for 10 
days starting on day 122. Phase 1 and 3 animals received a second course of treatment 
starting on days 193 and 200, respectively. Blood samples for PCR, IFA, flow cytometry and 
ear prick for blood smear examination were collected at multiple time points during the 
three phases of the study.
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Course of parasitemia in the two phase 1 rhesus macaques (RFl9, RGc8) transfused with 
hamster-passaged B. microti. The parasitemia values (left y axis) were compared with an 
IFA test titer (right y axis) and nested PCR. A titer of 1:64 with B. microti antigen was 
considered a positive reaction. Parasitemia levels determined on thick blood smears and 
qPCR were expressed as parasites/μL. Nested PCR results are reported as positive or 
negative. Arrows indicate initiation of atovaquone/azithromycin treatment.
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Parasitemia in the three phase 2 rhesus macaques (RLk10, RZz9, and RCq10) transfused 
with monkey-passaged B. microti. The parasitemia values (left y axis) were compared with 
an IFA test titer (right y axis) and nested PCR. A titer of 1:64 with B. microti antigen was 
considered positive. Parasitemia levels determined on thick blood smears and qPCR were 
expressed as parasites/μL. Nested PCR results are reported as positive or negative. Arrows 
indicate initiation of atovaquone/azithromycin treatment.
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Parasitemia in the one phase 3 rhesus macaque (RVf12) transfused with monkey-passaged 
B. microti. The parasitemia values (left y axis) were compared with an IFA test titer (right y 
axis) and nested PCR. A titer of 1:64 with B. microti antigen was considered positive. 
Parasitemia levels determined on thick blood smears and qPCR were expressed as parasites/
μL. Nested PCR results are reported as positive or negative. Arrows indicate initiation of 
atovaquone/azithromycin treatment.
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Activation of total and subpopulations of B cells in rhesus macaques during the course of the 
three phases of the study of B. microti infection. Lines represent the average Ki67 MFI for 
each phase with the error bars indicating standard deviation. MFI: mean fluorescence 
intensity.
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Table 1
Kinetics of parasitemia and antibody titers in the rhesus macaques infected with B. microti during the three 
phases of the study
Hamster-passaged B. microti Monkey-passaged B. microti
Screening Test Phase 1 Phase 2 Phase 3
qPCR parasitemia*
 First detection 35 4 4
 Peak detection 56–63 14–21 35
Blood smear parasitemia*
 First detection 49 4 21
 Peak detection 56–63 14–21 35
IFA titer*
 First response 35–49 14 21
 Peak response 56 21 35
*
Data correspond to respective study day(s) in the particular phase (Phase 1: monkeys RFl9 and RGc8; Phase 2: monkeys RLk10, RZz9, and 
RCq10; Phase 3: monkey RVf12)
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